drugset / Trial / NCT00250042
A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec
Non-randomizedSingle-groupOpen-labelTreatment
Summary
1.0 OBJECTIVES 1.1 To test the activity of arsenic trioxide in combination with imatinib in patients with CML with cytogenetic evidence of residual disease. 1.2 To determine the toxicity associated with this therapy.
Timeline
- Start
- 2004-04
- Primary completion
- 2005-04
- Completion
- 2006-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imatinib | Small molecule | 400 mg | — |
| Subject | Imatinib | Small molecule | 800 mg | — |
| Subject | arsenic trioxide | Small molecule | — | — |